NO981633L - Pharmaceutical surface preparation for administering an active compound to or through the skin or a mucosa surface - Google Patents
Pharmaceutical surface preparation for administering an active compound to or through the skin or a mucosa surfaceInfo
- Publication number
- NO981633L NO981633L NO981633A NO981633A NO981633L NO 981633 L NO981633 L NO 981633L NO 981633 A NO981633 A NO 981633A NO 981633 A NO981633 A NO 981633A NO 981633 L NO981633 L NO 981633L
- Authority
- NO
- Norway
- Prior art keywords
- analogs
- composition
- active substance
- prodrugs
- solubility
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Farmasøytiske sammensetninger for administrering av en aktiv substans til eller gjennom en skadet eller uskadet hud eller mukosaoverflate eller til det orale hulrommet inkludert tennene til et dyr slikt som et menneske. Blandingen har fordelaktige egenskaper med hensyn på frigjøring av den aktive substansen fra blandingen og, videre, er blandingen bioadhesiv. Blandingen innbefatter den aktive substansen og en effektiv mengde av en fettsyreester som, sammen med en flytende fase, kan generere en flytende krystallinsk fase der bestanddelene av blandingen er innesluttet, der den aktive substansen har en løselighet i den flytende krystallinske fasen på det meste 20 mg/g ved 20 °C, og en løselighet i vann på det meste 10 mg/ml ved 20 °C, vannet, der det er passende, er bufret til en pH som er vesentlig lik den pH som er rådende i den flytende krystallinske fasen (pH ca. 3,6-9). Blandingen er spesielt egnet for administrering av substanser som har en veldig lav vannløselighet og som skal bli gitt i en effektiv mengde til en lokalisert region over en tidsperiode. Aktive substanser med spesiell viktighet er anti-herpesvirusagenser inkludert antivirale legemidler og prodroger derav, slik som nukleosider, nukleosid- analoger, fosforylerte nukleosider (nukleotider), nukleotidanaloger og salter, komplekser og prodroger derav; f.eks. guanosinanaloger, deoksyguanosinanaloger, guanin, guaninanaloger, tymidinanaloger, uracilanaloger og adeninanaloger. Spesielt interessante anti-herpesvirusagenser til bruk enten alene eller i kombinasjon i en blanding i henhold til den foreliggende oppfinnelsen er valgt fra acyklovir, famciklovir, deciklovir, penciklovir, zidovudin, ganciklovir, didanosin, zalcitabin, valaciklovir, sorivudin, lobukavir, brivudin, cidofovir, n-dokosanol, ISIS-2922, og prodroger og analoger derav.Pharmaceutical compositions for the administration of an active substance to or through an injured or undamaged skin or mucosa surface or to the oral cavity including the teeth of an animal such as a human. The composition has advantageous properties in releasing the active substance from the composition and, further, the composition is bioadhesive. The composition includes the active substance and an effective amount of a fatty acid ester which, together with a liquid phase, can generate a liquid crystalline phase where the constituents of the mixture are enclosed, the active substance having a solubility in the liquid crystalline phase of at most 20 mg. / g at 20 ° C, and a solubility in water at most 10 mg / ml at 20 ° C, where appropriate, the water is buffered to a pH substantially equal to the pH prevailing in the liquid crystalline phase (pH about 3.6-9). The mixture is particularly suitable for the administration of substances which have a very low water solubility and to be delivered in an effective amount to a localized region over a period of time. Active substances of particular importance are anti-herpes virus agents including antiviral drugs and prodrugs thereof, such as nucleosides, nucleoside analogs, phosphorylated nucleosides (nucleotides), nucleotide analogs and salts, complexes and prodrugs thereof; eg. guanosine analogues, deoxyguanosine analogs, guanine, guanine analogs, thymidine analogs, uracil analogs and adenine analogs. Particularly interesting anti-herpes virus agents for use either alone or in combination in a composition of the present invention are selected from acyclovir, famciclovir, deciclovir, penciclovir, zidovudine, ganciclovir, didanosine, zalcitabine, valaciclovir, sorivudine, lobucavir, brivudine n-docosanol, ISIS-2922, and prodrugs and analogs thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK115095 | 1995-10-12 | ||
PCT/DK1996/000437 WO1997013528A1 (en) | 1995-10-12 | 1996-10-11 | A pharmaceutical composition for administration of an active substance to or through a skin or mucosal surface |
Publications (2)
Publication Number | Publication Date |
---|---|
NO981633D0 NO981633D0 (en) | 1998-04-08 |
NO981633L true NO981633L (en) | 1998-06-04 |
Family
ID=8101575
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO981633A NO981633L (en) | 1995-10-12 | 1998-04-08 | Pharmaceutical surface preparation for administering an active compound to or through the skin or a mucosa surface |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0871489A1 (en) |
JP (1) | JPH11513393A (en) |
AU (1) | AU702030B2 (en) |
CA (1) | CA2231273A1 (en) |
FI (1) | FI980822A0 (en) |
NO (1) | NO981633L (en) |
WO (1) | WO1997013528A1 (en) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6440980B1 (en) | 1996-09-17 | 2002-08-27 | Avanir Pharmaceuticals | Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs |
US6458373B1 (en) | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
EP0975331A1 (en) * | 1997-04-17 | 2000-02-02 | Dumex-Alpharma A/S | A novel bioadhesive drug delivery system based on liquid crystals |
ATE321882T1 (en) | 1997-07-01 | 2006-04-15 | Isis Pharmaceuticals Inc | COMPOSITIONS AND METHODS FOR ADMINISTRATION OF OLIGONUCLEOTIDES VIA THE ESOPHAUS |
CA2299298A1 (en) * | 1997-08-09 | 1999-02-18 | Jane Elizabeth Hilton | Compositions for nasal administration |
PL333331A1 (en) * | 1997-09-09 | 1999-12-06 | Select Release | Coated particles, method of producing them and their application |
SE9703458D0 (en) * | 1997-09-25 | 1997-09-25 | Pharmacia & Upjohn Ab | Nicotine compositions and methods of formulation thereof |
WO1999060012A1 (en) * | 1998-05-21 | 1999-11-25 | Isis Pharmaceuticals, Inc. | Compositions and methods for non-parenteral delivery of oligonucleotides |
US7030155B2 (en) | 1998-06-05 | 2006-04-18 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
GB9827034D0 (en) * | 1998-12-10 | 1999-02-03 | Univ Manchester | Delivery formulation |
EP1204407B1 (en) * | 1999-08-06 | 2004-10-27 | Max-Delbrück-Centrum Für Molekulare Medizin | Implantable active ingredient depot |
EP1239923A2 (en) * | 1999-12-20 | 2002-09-18 | New Pharma Research Sweden AB | Stabilized veterinary compositions comprising more than one antiviral agent |
DE10057769A1 (en) | 2000-11-22 | 2002-05-23 | Beiersdorf Ag | Use of a composition for cosmetic or dermatological hair care products, comprises dispersed liquid crystals forming a cubic phase as a base |
EP1390378B1 (en) * | 2001-04-30 | 2009-06-17 | Trommsdorff GmbH & Co. KG Arzneimittel | Pharmaceutically active uridine esters |
US7439271B2 (en) * | 2001-06-27 | 2008-10-21 | The Gillette Company | Reduction of hair growth |
US20030124196A1 (en) | 2001-08-22 | 2003-07-03 | Susan Weinbach | Pulsatile release compositions and methods for enhanced intestinal drug absorption |
EP1667656A4 (en) * | 2003-09-01 | 2011-12-28 | Mayne Pharma Int Pty Ltd | Compositions and methods for delivery of biologically active agents |
NZ551990A (en) | 2004-06-04 | 2011-01-28 | Camurus Ab | Liquid depot formulations |
WO2006036982A2 (en) | 2004-09-28 | 2006-04-06 | Atrium Medical Corporation | Drug delivery coating for use with a stent |
US9012506B2 (en) | 2004-09-28 | 2015-04-21 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
US9801982B2 (en) | 2004-09-28 | 2017-10-31 | Atrium Medical Corporation | Implantable barrier device |
US9000040B2 (en) | 2004-09-28 | 2015-04-07 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
WO2006037080A2 (en) | 2004-09-28 | 2006-04-06 | Atrium Medical Corporation | Uv cured gel and method of making |
ES2343641T3 (en) * | 2005-01-14 | 2010-08-05 | Camurus Ab | TOPIC BIOADHESIVE FORMULATIONS. |
DE602005026998D1 (en) | 2005-01-14 | 2011-04-28 | Camurus Ab | SOMATOSTATIN-ANALOG FORMULATIONS |
EP1843746B1 (en) * | 2005-01-14 | 2011-03-16 | Camurus Ab | Somatostatin analogue formulations |
US9649382B2 (en) | 2005-01-14 | 2017-05-16 | Camurus Ab | Topical bioadhesive formulations |
WO2006075125A1 (en) * | 2005-01-14 | 2006-07-20 | Camurus Ab | GnRH ANALOGUE FORMULATIONS |
CA2595385C (en) | 2005-01-21 | 2011-01-25 | Camurus Ab | Pharmaceutical lipid compositions |
EP1888038A2 (en) * | 2005-05-10 | 2008-02-20 | Novartis AG | Modified release famciclovir pharmaceutical compositions |
EP1888031B1 (en) | 2005-06-06 | 2013-01-23 | Camurus Ab | Glp-1 analogue formulations |
US8574627B2 (en) | 2006-11-06 | 2013-11-05 | Atrium Medical Corporation | Coated surgical mesh |
US9278161B2 (en) | 2005-09-28 | 2016-03-08 | Atrium Medical Corporation | Tissue-separating fatty acid adhesion barrier |
US9427423B2 (en) | 2009-03-10 | 2016-08-30 | Atrium Medical Corporation | Fatty-acid based particles |
AU2006304590A1 (en) | 2005-10-15 | 2007-04-26 | Atrium Medical Corporation | Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings |
NZ577020A (en) | 2006-10-17 | 2012-05-25 | Nuvo Res Inc | Diclofenac gel containing dimethyl sulfoxide (dmso) |
US9492596B2 (en) | 2006-11-06 | 2016-11-15 | Atrium Medical Corporation | Barrier layer with underlying medical device and one or more reinforcing support structures |
GB0711656D0 (en) | 2007-06-15 | 2007-07-25 | Camurus Ab | Formulations |
GB0716385D0 (en) | 2007-08-22 | 2007-10-03 | Camurus Ab | Formulations |
CA2727299C (en) * | 2008-06-09 | 2017-02-14 | Boehringer Ingelheim International Gmbh | Device and method for determining the properties of aerosol formulations |
GB0815435D0 (en) | 2008-08-22 | 2008-10-01 | Camurus Ab | Formulations |
US8618164B2 (en) | 2009-03-31 | 2013-12-31 | Nuvo Research Inc. | Treatment of pain with topical diclofenac compounds |
US8546450B1 (en) | 2009-03-31 | 2013-10-01 | Nuvo Research Inc. | Treatment of pain with topical diclofenac compounds |
WO2010150262A2 (en) * | 2009-06-25 | 2010-12-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Reverse hexagonal mesophases (hii) and uses thereof |
US20110038910A1 (en) | 2009-08-11 | 2011-02-17 | Atrium Medical Corporation | Anti-infective antimicrobial-containing biomaterials |
WO2012009707A2 (en) | 2010-07-16 | 2012-01-19 | Atrium Medical Corporation | Composition and methods for altering the rate of hydrolysis of cured oil-based materials |
MA37672A1 (en) | 2012-05-25 | 2016-07-29 | Camurus Ab | Somatostatin receptor agonist formulation |
US9867880B2 (en) | 2012-06-13 | 2018-01-16 | Atrium Medical Corporation | Cured oil-hydrogel biomaterial compositions for controlled drug delivery |
US9937164B2 (en) | 2012-07-26 | 2018-04-10 | Camurus Ab | Opioid formulations |
WO2018191794A1 (en) | 2017-04-20 | 2018-10-25 | Zeenar Enterprises Pty Ltd | Liquid crystalline dosage form for administering a statin |
CN112770778A (en) * | 2018-09-07 | 2021-05-07 | 法纳克斯株式会社 | External preparation containing non-lamellar liquid crystal forming lipid |
CA3117606A1 (en) * | 2018-10-25 | 2020-04-30 | Zeenar Enterprises Pty Ltd | Composition that forms liquid crystalline particles |
CN111821254B (en) * | 2019-04-18 | 2021-10-15 | 华东师范大学 | Antiviral hydrogel and preparation method and application thereof |
CN111759858B (en) * | 2020-06-02 | 2022-09-20 | 杭州英健生物科技有限公司 | PH-sensitive digestive tract mucosa protective gel and application thereof |
CN112791047A (en) * | 2021-01-15 | 2021-05-14 | 中国人民解放军总医院第三医学中心 | Resveratrol lamellar liquid crystal and preparation method thereof |
CA3235606A1 (en) * | 2021-10-19 | 2023-04-27 | Sensach Ab | Lipid patch |
WO2023189273A1 (en) * | 2022-03-28 | 2023-10-05 | 富士フイルム株式会社 | Biological composition |
WO2023189270A1 (en) * | 2022-03-28 | 2023-10-05 | 富士フイルム株式会社 | Biomaterial composition |
WO2024068672A1 (en) * | 2022-09-26 | 2024-04-04 | Universität Bern | Structured lipid compositions |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2631282A1 (en) * | 1976-07-12 | 1978-01-19 | Kali Chemie Pharma Gmbh | Increasing solubility of pharmaceutical used e.g. in gelatin capsules - by dissolving in fatty acid mono:glyceride cpds. and then rapidly cooling |
SE457933B (en) * | 1987-07-06 | 1989-02-13 | Larsson Kare | PHARMACEUTICAL COMPOSITION INCLUDING A WATER DISPERSED MIXTURE OF LIPIDS, MONOGLYCERIDES AND PHOSPHATIDYLCOLINE AND ITS APPLICATION FOR THE PREPARATION OF A GASTRONIN TESTINALLY EFFECTIVE COMPOSITION |
CA2038744C (en) * | 1990-03-23 | 2002-01-08 | Yoshitomi Pharmaceutical Industries Ltd. | Pharmaceutical composition containing slightly water-soluble drug |
ATE180971T1 (en) * | 1994-03-30 | 1999-06-15 | Gs Dev Ab | USE OF FATTY ACID ESTERS AS BIO ADHESIVES |
-
1996
- 1996-10-11 WO PCT/DK1996/000437 patent/WO1997013528A1/en not_active Application Discontinuation
- 1996-10-11 AU AU72792/96A patent/AU702030B2/en not_active Ceased
- 1996-10-11 EP EP96934441A patent/EP0871489A1/en not_active Withdrawn
- 1996-10-11 CA CA002231273A patent/CA2231273A1/en not_active Abandoned
- 1996-10-11 JP JP9514651A patent/JPH11513393A/en active Pending
-
1998
- 1998-04-08 NO NO981633A patent/NO981633L/en not_active Application Discontinuation
- 1998-04-09 FI FI980822A patent/FI980822A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP0871489A1 (en) | 1998-10-21 |
FI980822A (en) | 1998-04-09 |
WO1997013528A1 (en) | 1997-04-17 |
CA2231273A1 (en) | 1997-04-17 |
JPH11513393A (en) | 1999-11-16 |
AU7279296A (en) | 1997-04-30 |
NO981633D0 (en) | 1998-04-08 |
FI980822A0 (en) | 1998-04-09 |
AU702030B2 (en) | 1999-02-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO981633L (en) | Pharmaceutical surface preparation for administering an active compound to or through the skin or a mucosa surface | |
Mahmoud et al. | Antiviral nucleoside and nucleotide analogs: a review | |
MY121839A (en) | Antiviral purine derivatives | |
KR900015742A (en) | Antiviral agents | |
EA005774B1 (en) | 3'-PRODRUGS OF 2'-DEOXY-beta-L-NUCLEOSIDES | |
US20090192077A1 (en) | North-2'deoxy -methanocarbathymidines as antiviral agents for treatment of kaposi's sarcoma-associated herpes virus | |
CZ20023051A3 (en) | Nucleoside analog and use thereof | |
RU2006147216A (en) | BETA-L-2` DESOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS IN | |
BR0008498A (en) | Method of promoting hydration of mucous membranes with certain uridine, adenine and cytidine diphosphates and their analogs | |
JP2005508297A5 (en) | ||
HU198394B (en) | Process for production of synergetic antiviral medical composition | |
Herdewijn | Novel nucleoside strategies for anti-HIV and anti-HSV therapy | |
Seley-Radtke et al. | Broad spectrum antiviral nucleosides—Our best hope for the future | |
KR100632520B1 (en) | Combination Therapies to Treat Hepatitis B Virus | |
SI9820003A (en) | Cytokine related treatments of disease | |
WO2006013203A2 (en) | Prodrugs activated by rna-dependent dna-polymerases | |
EP2968228A1 (en) | Combined systemic and topical treatment of disordered tissues | |
US11945833B2 (en) | Prodrugs of L-BHDU and methods of treating viral infections | |
US8524690B2 (en) | DNA polymerase inhibitors composition and methods | |
US4044122A (en) | Method of treating herpes virus hominis infections | |
RU98100411A (en) | ACYCLOVIR DERIVATIVES FOR LOCAL USE | |
LIANG et al. | Research Progress in Phosphorylation Modification of Antiviral Nucleotide Analogs | |
US20090004101A1 (en) | Method and Means for Enhanced Pulmonary Drug Delivery | |
De Clercq | Antiviral drugs: Triphosphates of nucleoside analogues active as antiviral drugs | |
ECSP993155A (en) | CHEMICAL COMPOUNDS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |